Table 2. Changes in Metabolic Parameters After the Start of Oral Semaglutide in All Patients (N = 47).
| N | Baseline | After 3 months | N | Baseline | After 6 months | |
|---|---|---|---|---|---|---|
| Body weight (kg) | 40 | 78.9 ± 17.7 | 77.5 ± 17.9** | 25 | 79.7 ± 19.3 | 77.3 ± 19.5** |
| Systolic blood pressure (mm Hg) | 41 | 133.1 ± 14.1 | 130.1 ± 15.8 | 25 | 134.0 ± 14.7 | 127.8 ± 14.3** |
| Diastolic blood pressure (mm Hg) | 41 | 77.9 ± 10.6 | 76.7 ± 11.7 | 25 | 77.9 ± 10.6 | 77.0 ± 12.6 |
| Plasma glucose (mg/dL) | 40 | 179.2 ± 96.1 | 170.6 ± 57.8 | 26 | 183.5 ± 116.2 | 162.3 ± 63.1 |
| HbA1c (%) | 41 | 8.1 ± 1.5 | 7.9 ± 1.5* | 26 | 8.4 ± 1.5 | 7.8 ± 1.5** |
| AST (IU/L) | 41 | 30.3 ± 17.3 | 29.0 ± 14.3 | 28 | 32.1 ± 19.3 | 31.0 ± 20.0 |
| ALT (IU/L) | 41 | 43.2 ± 32.5 | 40.4 ± 27.6 | 28 | 45.0 ± 35.0 | 41.0 ± 35.0 |
| GGT (IU/L) | 36 | 49.5 ± 43.8 | 45.5 ± 37.1 | 24 | 56.3 ± 51.2 | 53.0 ± 51.0 |
| TG (mg/dL) | 39 | 205.5 ± 129.2 | 199.0 ± 168.9 | 26 | 210.9 ± 137.5 | 190.2 ± 123.9 |
| HDL-C (mg/dL) | 39 | 52.2 ± 13.5 | 51.0 ± 11.5 | 26 | 50.8 ± 14,1 | 49.2 ± 13.1 |
| LDL-C (mg/dL) | 37 | 96.8 ± 28.5 | 92.5 ± 25.6 | 26 | 101.0 ± 31.0 | 91.3 ± 25.5** |
| Non-HDL-C (mg/dL) | 36 | 128.3 ± 36.6 | 125.0 ± 36.1 | 24 | 132.0 ± 39.6 | 122.2 ± 31.7* |
| UA (mg/dL) | 39 | 5.1 ± 1.2 | 4.9 ± 1.3 | 27 | 5.1 ± 1.5 | 5.1 ± 1.2 |
| eGFR (mL/min/1.73 m2) | 41 | 80.5 ± 25.3 | 82.5 ± 25.3 | 28 | 80.6 ± 26.8 | 78.7 ± 26.8 |
| UACR | 25 | 107.9 ± 224.9 | 62.5 ± 117.4* | 14 | 123.1 ± 255.8 | 93.9 ± 211.8* |
Values were shown as mean ± SD. *P < 0.1, **P < 0.05 vs. baseline. HbA1c: hemoglobin A1c; ALT: alanine aminotransferase; AST: aspartate aminotransferase; eGFR: estimated glomerular filtration rate; GGT: gamma-glutamyl transferase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; non-HDL-C: non-high-density lipoprotein cholesterol; TG: triglyceride; UA: uric acid; UACR: urinary albumin to creatinine ratio.